ThymoFox
Biotechnology company focused on identifying compounds that induce regeneration and rejuvenation of the thymus to restore immune function in age-related diseases and immunocompromised conditions.
Website
https://www.thymofox.comLocation
Berlin, Germany
Founded
2020
Investors
1
Categories
biotech, immunology, longevity, thymus, regenerative-medicine
Notes
ThymoFox is a biotechnology company focused on identifying compounds that induce regeneration and rejuvenation of the thymus. The thymus is a critical organ for immune system function, producing T cells that are essential for adaptive immunity. However, the thymus begins to shrink (involute) after puberty, contributing to age-related immune decline.
ThymoFox is developing therapeutics to restore thymus function, which could:
- Improve immune function in elderly patients
- Enhance recovery from immunosuppressive treatments (chemotherapy, bone marrow transplant)
- Treat age-related immune decline (immunosenescence)
- Potentially improve vaccine responses in older adults
The company is backed by Apollo Health Ventures, which focuses on longevity and aging-related biotechnology.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Portfolio company of Apollo Health Ventures
- Focus on thymus regeneration and rejuvenation
- Immunosenescence targeting
- Longevity therapeutics
- Berlin, Germany headquarters
- Founded in 2020
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apollo Health Ventures | Dusseldorf, Germany / Boston, USA | biotech-focused | seedseries-a+1 | 15 |